Scienture LLC Leadership

Executive Management

Scienture Inc

Shankar Hariharan, Ph.D.

Founder & CEO

Shankar Hariharan

Ph.D. (Founder & CEO)

Dr. Hariharan is the Founder, President and CEO of Scienture, Inc. Dr. Hariharan has over 35 years of experience in successfully leading branded, specialty and generic pharmaceutical businesses and has held several leadership positions at Forest Labs, Par Pharmaceuticals and Amneal Pharmaceuticals.

At Amneal in his role as the Executive Vice President and Chief Scientific Officer, he oversaw Global Research & Development, Global Regulatory Affairs, and Specialty Product Development and was instrumental in the company achieving significant revenue growth (>$1.5B) with high profit margins.

Prior to joining Amneal, Dr. Hariharan founded DermAct, an R&D organization specializing in new molecule discovery and product development for key indications in Dermatology, leading to the company’s successful acquisition.

Some notable blockbuster drug products, offering unique value to patients and caregivers, brought to market under Dr. Hariharan’s leadership include Celexa® (>$2B), Lexapro® ($ 4B), Namenda® (>$2B), Megace ES® (>$100M) and over 200 generic products (including many complex generic products). Dr. Hariharan obtained his bachelor’s degree in pharmacy at the Banaras Hindu University (BHU) in India and his Ph.D. in Pharmaceutical Sciences at Northeastern University in Boston, Massachusetts.

Dr. Hariharan currently serves on the Board of Depymed, Inc. and on the Advisory Board of New Rhein Healthcare, LLC and MAA Laboratories.

Read More
Narasimhan Mani, Ph.D., MBA

Narasimhan Mani, Ph.D., MBA

President

Narasimhan Mani, Ph.D., MBA

(President)

Dr. Narasimhan Mani is an experienced healthcare professional with over 25 years of experience in the pharmaceutical industry. He most recently served as the President & CEO for Kesin Pharma Corporation, a Specialty Pharma company with a focus on commercializing specialty and brand products. His past roles include serving as the CEO of Xiromed LLC, a Generics and Specialty drug product company and as the VP, Global Corporate Strategy and BD, at Amneal Pharmaceuticals where he led all the company's strategic initiatives across Global Strategy, Portfolio Management, Business Development and Commercial Operations. His previous experiences also include being the Corporate Finance and Strategic Planning Leader at Johnson & Johnson in New Brunswick, NJ in the pharmaceutical and medical device sectors. He also worked as a Research Scientist and product development leader during his time at Forest Laboratories and Par Pharmaceuticals. He continues to be part of the Executives-in-Residence at New Rhein Healthcare Investors, a life-sciences focused private equity firm and serves as a Board Member at Corsair Pharma, Inc. one of their portfolio companies.

Dr. Mani’s journey in the pharmaceutical and healthcare sectors began with his B.Pharm (Hons.). from BITS, Pilani, India which he completed in 1995. His subsequent graduate degrees include M.S. Analytical Chemistry, from the University of Oklahoma, Norman in 1998, Ph.D. in Pharmaceutics, from the University of Georgia, Athens in 2003 and MBA in Finance and Marketing, from Columbia Business School, New York, NY in 2008. Dr. Mani is also the recipient of the 2021 Outstanding 50 Asian Americans in Business Award, in September 2021.

Read More
Rahul Surana

Rahul Surana, Ph.D., MBA

EVP & COO

Rahul Surana

EVP & COO

Results-driven pharmaceutical executive with a proven track record in pharmaceutical development, strategic leadership, and business development. Over 20 years of brand and generic industry experience working for small, medium and large pharmaceutical companies in various capacities.

Read More
New Project - 2022-03-30T092848.428

Shreena Patel

Vice President, Regulatory Affairs & Project Management

Shreena Patel

(Vice President, Regulatory Affairs & Project Management)
Seasoned regulatory professional with over 14 years of experience in handling the submissions of new drug applications and abbreviated new drug applications to FDA. Shreena has led cross-functional teams to achieve several 505(j), 505(b)(2) and 505 (b)(1) applications for various drug product dosage forms (solid, liquid, topical, nasal, transdermal and injectable products) across a broad range of therapeutic categories. She has efficiently worked on several pre- and post-approval IND, NDA and ANDA eCTD submissions including First to File opportunities and worked with multiple Clinical Research Organizations (CROs) to ensure good quality US FDA submissions. Shreena has coordinated several product development meetings, pre-submission meetings and mid-cycle-review meetings with FDA. She has efficiently managed regulatory staff working in different time zones and worked successfully on defining key product submission strategies based on ICH and FDA guidelines.

Read More
MRATH_6971bweb

Michele Rath

SVP and Chief Commercial Officer

Michele Rath

SVP and Chief Commercial Officer

Michele Rath is a healthcare and pharmaceutical professional with over 25 years of experience in Sales & Marketing, pipeline development, market access strategy, pricing & contracting, and new product launches. She has commercial experience across various drug archetypes including sterile injectables, oral solids, biosimilars and branded 505(b)(2) assets. Michele has held a variety of key roles at Cardinal Health, CVS Health (Caremark), Pfizer (Hospira), AuroMedics Pharma (Eugia), and Fresenius Kabi USA, where she managed portfolios for products like Zosyn®, Zyvox®, Diprivan®, Naropin® and Retacrit® one of Pfizer’s first biosimilars.

She holds a Bachelor of Science in Business Administration from Northern Illinois University.

Read More

Scientific Advisory Board

Scienture Inc

Suneel Gupta

Ph.D.

Suneel Gupta

Ph.D. 

An executive and an entrepreneur with 30 years of experience in discovering, developing and registering several pharmaceutical products (Duragesic, Concerta, Ionsys, Invega, and Rytary).

Dr. Gupta is chief development officer at Protagonist Therapeutics. His prior professional roles include SVP of R & D (Alza/J&J), CSO of ImpaxLabs. His areas of expertise include: Clinical Pharmacology, Clin Research & Dev, Drug Delivery, 505b(2), Formulation, Drug Safety, Medical Affairs, Pharmaceutical product production

Read More
Scienture Inc

Wantanee Phuapradit

Ph.D.

Wantanee Phuapradit

Ph.D.

Twenty-eight years of experience in pharmaceutical product development of new chemical entities, specialty products, and complex generics.

Her professional experience includes senior roles at Hoffman La Roche, Barr/Teva and Kashiv Pharma with expertise in all areas of pharmaceutics and development including modified release technology and differentiated complex dosage form development. She is a co-inventor of 20 drug delivery patents.

Read More
Scienture Inc

Lawrence Olanoff

M.D., Ph.D.

Lawrence Olanoff

M.D., Ph.D.

Lawrence Olanoff is an adjunct Assistant Professor and Special Advisor to the President for Corporate Relations at the Medical University of South Carolina. From 2006-2010, he served as President and Chief Operating Officer for Forest Laboratories, Inc. From 2005 to 2006, Dr. Olanoff was CEO of Celsion Corporation. Prior to 2005, he served as Executive VP of Research and Development and Chief Scientific Officer of Forest, and held senior clinical research roles at Sandoz Pharmaceutical Corporation and the Upjohn Company. During his pharmaceutical development career, Dr. Olanoff made substantial contributions leading to thirty new drug approvals, either as new chemical entities or as supplemental indications, over a range of therapeutic areas. He is Chairman of the board of directors of Mitochondria in Motion, and serves as a member of the Board of Ironwood Pharmaceuticals and Ichnos Sciences, as well as several non-profit organizations. Dr. Olanoff also held past directorships on the boards of Forest Laboratories, Axovant Sciences Ltd. and the Celsion Corporation. He received his Ph.D. in biomedical engineering and M.D. degree from Case Western Reserve University, was an internal medicine resident and clinical pharmacology fellow at the Medical University of SC and is the author of some 40 scientific publications on topics including controlled drug delivery, pharmacokinetics, drug metabolism and clinical toxicology.

Read More